How do I figure out the estimated incidence rate of COVID-19 in the vaccine arm of the trial (left side of the chart)N=18,198Overall 8 had casesSurveillance time (no at risk): 2.224 (17,411)

total number of Covid-19 infections incurred among receiving the second dose of the 2-dose vaccine regimen. Table 3. Vaccine Efficacy Overall and by Subgroup in Participants without Evidence of Infection before 7 Days after Dose 2. Efficacy End-Point BNT16262 Placebo Vaccine Efficacy, % Subgroup (N=18,198) (N=18,325) (95% CIT Surveillance Surveillance No. of Time No. of Time Cases (No. at Risk)* Cases (No. at Risk)* Overall 8 2.214 (17,411) 162 2.222 (17,511) 95.0 (90.0-97.9) Age group 16 to $5 yr S 1.234 (9,897) 114 1.239 (9,955) 95.6 (89.4 98.6) >5S yr 0.980 (7,500) 48 0.983 (7,543) 93.7 (80.6 98.8) 265 yr ON W 0.508 (3,848) 19 0.511 (3,880) 94.7 (66.7-99.9) 275 yr 0.102 (774) 5 0.106 (785) 100.0 (-13.1-100.0) Sex Male 1.124 (8,875) 81 1.108 (8,762) 96.4 (88.9 99.3) in w Female 1.090 (8,536) 81 1.114 (8,749) 93.7 (84.7-98.0) Race or ethnic group White 1.889 (14,504) 146 1.903 (14,670) 95.2 (89.8-98.1) Black or African American 0.165 (1,502) 7 0.164 (1,486) 100.0 (31.2-100.0) All others 0.160 (1,405) 9 0.155 (1,355) 89.3 (22.6 99.8) Hispanic or Latinx 0.605 (4,764) 53 0.600 (4,746) 94.4 (82.7-98.9) Non-Hispanic, non-Latinx 1.596 (12,548) 109 1.608 (12,661) 95.4 (88.9-98.5) Country Argentina 0.351 (2,545) 35 0.346 (2.521) 97.2 (83.3-99.9) Brazil 0.119 (1,129) 0.117 (1,121) 87.7 (8.1-99.7) United States 1.732 (13,359) 119 1,747 (13,506) 94.9 (88.6-98.2) *Surveillance time is the total time in 1000 person-years for the given end point across all participants within each group at risk for the end point. The time period for Covid-19 case accrual is from 7 days after the second dose to the end of the surveillance period. The confidence interval (CI) for vaccine efficacy is derived according to the Clopper-Pearson method, adjusted for surveillance time. Race or ethnic group was reported by the participants. "All others" included the following categories: American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, multiracial, and not reported. What is the overall estimated incidence rate of Covid-19 in the vaccine (BNT162b2) arm of the trial? a. 8 cases per 17,411 person years